Fig. 9
Sensitivity analysis showing that if the probability of a positive clinicial response to Cyclosporine A (Restasis) is >96% at month 4, then Cyclosporine A (Restasis) becomes the less expensive option
Fig. 9 | Cost Effectiveness and Resource Allocation